为什么酪氨酸激酶抑制剂耐药在晚期胃肠道间质瘤中很常见。
Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors.
作者信息
Tomasetti Cristian, Demetri George D, Parmigiani Giovanni
机构信息
Department of Biostatistics, Harvard School of Public Health, Boston MA, 02215, USA ; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston MA, 02215, USA ; Current affiliation: Division of Biostatistics & Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD , 21205-2013 , USA ; Current affiliation: Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205-2179 , USA.
Ludwig Center for Cancer Research at Dana-Farber Cancer Institute and Harvard Medical School, Boston MA, 02215, USA ; Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston MA, 02215, USA.
出版信息
F1000Res. 2013 Jul 9;2:152. doi: 10.12688/f1000research.2-152.v1. eCollection 2013.
BACKGROUND
Most patients with advanced gastrointestinal stromal tumors (GIST) develop drug resistance to tyrosine kinase inhibitors (TKIs) within two years of starting therapy, whereas most chronic myeloid leukemia (CML) patients in chronic phase still exhibit disease control after a decade on therapy. This article aims to explain this divergence in long term outcomes.
METHODS AND RESULTS
By combining clinical and experimental observations with mathematical formulas we estimate that, in advanced GIST, the genetic changes responsible for resistance are generally already present at disease detection.
CONCLUSION
This result has relevant clinical implications by providing support for the exploration of combination therapies.
背景
大多数晚期胃肠道间质瘤（GIST）患者在开始治疗后的两年内会对酪氨酸激酶抑制剂（TKIs）产生耐药性，而大多数慢性期慢性髓性白血病（CML）患者在接受治疗十年后仍能实现疾病控制。本文旨在解释这种长期结果上的差异。
方法与结果
通过将临床和实验观察结果与数学公式相结合，我们估计，在晚期GIST中，导致耐药性的基因变化在疾病检测时通常已经存在。
结论
这一结果为联合治疗的探索提供了支持，具有相关的临床意义。
Zotero 插件